Schrödinger

Transforming drug discovery and materials research

Founded 1990

New York, United States 992 employees IPO Total: $871.40M Biotechnology, Enterprise Software +1

General Information

Company Name Schrödinger

Founded Year 1990

Location

New York, United States

Employees 992

Industries Biotechnology, Enterprise Software, Pharmaceutical

Funding Stage IPO

Business Model B2B, SaaS, B2C

Revenue Model Subscription, Licensing, Service Fee

Social

BounceWatch is an independent company data service, not affiliated with Schrödinger. To contact Schrödinger, visit schrodinger.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Schrödinger compare?

A PDF of Schrödinger and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Schrödinger soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

AI Insight

Bounce Watch AI

1 month ago

Schrödinger is making significant strategic advancements, marked by the launch of 'Bunsen,' an agentic AI co-scientist aimed at accelerating complex formulation discovery. This innovative product development, alongside a successful drug discovery collaboration with Structure Therapeutics, underscores the company's commitment to leveraging its computational platform for cutting-edge R&D. Their upcoming participation in the Global Polymer Summit further highlights a strategic focus on expanding their footprint and market reach within materials science.

Signal Types

Product Launch Partnership Market Expansion

Strategic Labels

AI Integration R&D Acceleration Platform Expansion

Next Move: Product Adoption

Impact: 9/10

Ideal For: Deep Tech & Life Sciences Investors - Public Market

About Schrödinger

Schrödinger, founded in 1990, is a frontrunner in the realms of Biotechnology, Enterprise Software, and Pharmaceutical industries. Headquartered in the United States, the company leverages its cutting-edge computational platform to advance drug discovery and materials research.

The firm's platform supports the research initiatives of biopharmaceutical companies, academic institutions, and government laboratories across over 70 countries, emphasizing a commitment to scientific innovation and cultivating top-tier talent. Moreover, Schrödinger operates its own drug discovery programs in diverse therapeutic areas, both independently and in collaboration with other entities.

The company recently received a $10.00 million grant investment from the Bill & Melinda Gates Foundation on 01 July 2024, signaling strong confidence in its potential to revolutionize its field. Vigilance against recruitment scams underscores Schrödinger's focus on integrity and trust in its interactions.

Business keywords: Computational Platform, Drug Discovery, Biopharmaceutical Research, Materials Research, Academic Partnerships, Government Collaborations, Therapeutic Areas, Scientific Investment, Technology Development, Collaborative Programs, Research Facilitation, Industrial Solutions, Talent Development, Recruitment Security

Services & Products

Software development for molecular discovery

Predictive computational platform

Drug discovery solutions

Materials science solutions

Clinical program management

Collaborative and proprietary drug discovery programs

Target Customers

Biotech companies Pharmaceutical companies Academics Research institutions Chemical manufacturers Consumer packaged goods industries Oil and gas industries

Funding Rounds & Investors (10)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	$10.00M	1	Bill & Melinda Gates Foundation	01 Jul 2024
Grant	$4.90M	1	Bill & Melinda Gates Foundation	01 Nov 2021
Post-IPO Equity	$346.50M	-		01 Aug 2020
IPO	$232.00M	-		01 Feb 2020
Series F	$110.00M	4	Bill & Melinda Gates Foundation, Invus +2	01 May 2019
Late VC	$85.00M	4	Qiming Venture Partners, Bill & Melinda Gates Foundation +2	01 Jan 2019
Growth Equity VC	$22.00M	1	Becker Ventures	01 Jun 2015
Growth Equity VC	$20.00M	1	Bill Gates	01 Dec 2012
Late VC	$10.00M	2	Bill Gates, Cascade Investment	01 Apr 2010
Series A	$31.00M	-		01 Mar 2002

Schrödinger Alternatives & Competitors

Schrödinger vs

NextBio United States

NextBio is the provider of an innovative platform that enables life science researchers to search, d...

Series C

32 employees

Biotechnology, Enterprise Software

Schrödinger vs

BiomX (NYSE: PHGE) Israel

$PHGE

IPO

35 employees

Biotechnology, Health Care

Schrödinger vs

Taros Discovery Germany

Advancing Human Health with Pioneering Chemistry. Committed to Innovation, Quality, and Your R&D Suc...

45 employees

Biotechnology, Life Sciences

FAQ About Schrödinger

Transforming drug discovery and materials research

Schrödinger was founded in 1990.

Schrödinger is headquartered in New York, United States.

Schrödinger operates in Biotechnology, Enterprise Software and Pharmaceutical. Its work centres on Computational Platform, Drug Discovery, Biopharmaceutical Research and Materials Research. Its customers include Biotech companies, Pharmaceutical companies and Academics.

Schrödinger has a B2B, SaaS and B2C business model. Its revenue comes from Subscription, Licensing and Service Fee.

Schrödinger has approximately 992 employees.

Schrödinger has completed 10 funding rounds, raising a total of $871.40M. The latest funding stage is IPO.

Schrödinger offers: Software development for molecular discovery, Predictive computational platform, Drug discovery solutions, Materials science solutions, Clinical program management, Collaborative and proprietary drug discovery programs.

Top alternatives and competitors to Schrödinger include NextBio, BiomX (NYSE: PHGE), Taros Discovery, XtalPi Inc., Cure51. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Schrödinger and NextBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Schrödinger, https://bouncewatch.com/company/schrodinger, updated 22 September 2026. When citing, please name BounceWatch and link this page.

Schrödinger

General Information

Discover More

AI Insight

About Schrödinger

Services & Products

Target Customers

Funding Rounds & Investors (10)

Schrödinger Alternatives & Competitors

FAQ About Schrödinger